|
gptkbp:instanceOf
|
gptkb:drug
selective serotonin 5-HT4 receptor agonist
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:A06AX17
|
|
gptkbp:bioavailability
|
93-95%
|
|
gptkbp:brand
|
gptkb:Motegrity
gptkb:Resolor
|
|
gptkbp:CASNumber
|
gptkb:179474-86-7
|
|
gptkbp:chemicalClass
|
benzofuran derivative
|
|
gptkbp:contraindication
|
gptkb:Crohn's_disease
ulcerative colitis
intestinal perforation
obstructive ileus
|
|
gptkbp:discoveredBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:eliminationHalfLife
|
24-30 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C18H26ClN3O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
prucalopride
|
|
gptkbp:indication
|
treatment of chronic constipation in children (in some countries)
treatment of chronic constipation in adults
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
Rx-only (US, EU)
|
|
gptkbp:marketedAs
|
gptkb:Takeda
gptkb:Shire
|
|
gptkbp:mechanismOfAction
|
stimulates colonic peristalsis
|
|
gptkbp:metabolism
|
minimal hepatic
|
|
gptkbp:molecularWeight
|
367.87 g/mol
|
|
gptkbp:notRecommendedFor
|
irritable bowel syndrome
opioid-induced constipation
|
|
gptkbp:patent
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
27-37%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
gptkb:DB06213
9941576
8117018
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
headache
|
|
gptkbp:UNII
|
K7V3B6Y6ZG
|
|
gptkbp:usedFor
|
chronic idiopathic constipation
|
|
gptkbp:bfsParent
|
gptkb:Resolor
|
|
gptkbp:bfsLayer
|
6
|